- Home
- NAN vs VYGR Comparison
NAN vs VYGR Comparison
Compare NAN & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAN
- VYGR
- Stock Information
- Founded
- NAN 1999
- VYGR 2013
- Country
- NAN United States
- VYGR United States
- Employees
- NAN N/A
- VYGR N/A
- Industry
- NAN Investment Managers
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- NAN Finance
- VYGR Health Care
- Exchange
- NAN Nasdaq
- VYGR Nasdaq
- Market Cap
- NAN 350.0M
- VYGR 342.5M
- IPO Year
- NAN N/A
- VYGR 2015
- Fundamental
- Price
- NAN $11.36
- VYGR $5.07
- Analyst Decision
- NAN
- VYGR Strong Buy
- Analyst Count
- NAN 0
- VYGR 9
- Target Price
- NAN N/A
- VYGR $15.53
- AVG Volume (30 Days)
- NAN 74.6K
- VYGR 385.3K
- Earning Date
- NAN 01-01-0001
- VYGR 02-26-2025
- Dividend Yield
- NAN 4.37%
- VYGR N/A
- EPS Growth
- NAN N/A
- VYGR N/A
- EPS
- NAN N/A
- VYGR 0.47
- Revenue
- NAN N/A
- VYGR $163,784,000.00
- Revenue This Year
- NAN N/A
- VYGR N/A
- Revenue Next Year
- NAN N/A
- VYGR N/A
- P/E Ratio
- NAN N/A
- VYGR $10.87
- Revenue Growth
- NAN N/A
- VYGR 3.40
- 52 Week Low
- NAN $9.11
- VYGR $4.99
- 52 Week High
- NAN $11.34
- VYGR $10.66
- Technical
- Relative Strength Index (RSI)
- NAN 49.99
- VYGR 34.22
- Support Level
- NAN $11.16
- VYGR $4.99
- Resistance Level
- NAN $11.38
- VYGR $5.45
- Average True Range (ATR)
- NAN 0.15
- VYGR 0.26
- MACD
- NAN 0.01
- VYGR -0.07
- Stochastic Oscillator
- NAN 42.86
- VYGR 6.25
About NAN Nuveen New York Quality Municipal Income Fund
Nuveen New York Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal, New York State and New York City income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.